CompletedNCT03172871
Aripiprazole Injection Compared With Tablets for Acute Schizophrenia
About this title
Read the official source — NCT03172871Medication studyAges 18–65China
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- BeijingSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: May 15, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 436
- Sponsor
- Otsuka Beijing Research Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03172871
- Official title
Show the full official title
A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beijing
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Beijing Research Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole IM Depot and Aripiprazole tablet.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
